3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial
Fichier principal
2022_PIONEER_ESMO_IO_MiniOral_edited_metadata.pdf (1.28 Mo)
Télécharger le fichier
Origin | Files produced by the author(s) |
---|